RA Capital Management’s Centessa Pharmaceuticals CNTA Stock Holding History

RA Capital Management’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,577,094	Closed	-$32.1M	–	91
2022 Q1	$32.1M	Hold	3,577,094	–	–	0.7%	43
2021 Q4	$40.3M	Hold	3,577,094	–	–	0.71%	41
2021 Q3	$59.7M	Buy	3,577,094 +2,296,794	+179%	+$47.5M	0.83%	36
2021 Q2	$28.4M	Buy	+1,280,300	New	+$30.1M	0.46%	56

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

OMC

OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

RA Capital Management's CNTA Position: Q2 2022 in Review

RA Capital Management sold out of Centessa Pharmaceuticals (CNTA) in Q2 2022, closing a stake of 3,577,094 shares — an estimated $32.1M sold.

RA Capital Management first reported a position in CNTA in Q2 2021 and held it in 4 quarters. The position peaked at $59.7M in Q3 2021. 41 funds tracked by Wall St. Rank hold CNTA as of Q2 2022.

RA Capital Management reported no remaining Centessa Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
RA Capital Management sold 3,577,094 Centessa Pharmaceuticals shares in Q2 2022, an estimated $32.1M.
RA Capital Management first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 4 quarters.
RA Capital Management's Centessa Pharmaceuticals position peaked at $59.7M in Q3 2021.
41 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2022.

Based on RA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.